Gilead Sciences, Inc. (ETR:GIS)
106.54
-0.24 (-0.22%)
Nov 6, 2025, 5:35 PM CET
Gilead Sciences Employees
Gilead Sciences had 17,600 employees as of December 31, 2024. The number of employees decreased by 400 or -2.22% compared to the previous year.
Employees
17,600
Change (1Y)
-400
Growth (1Y)
-2.22%
Revenue / Employee
€1,408,571
Profits / Employee
€392,736
Market Cap
132.85B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17,600 | -400 | -2.22% |
| Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
| Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
| Dec 31, 2021 | 14,400 | 800 | 5.88% |
| Dec 31, 2020 | 13,600 | 1,800 | 15.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Bayer Aktiengesellschaft | 91,864 |
| Siemens Healthineers AG | 72,000 |
| Merck KGaA | 59,020 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,730 |
Gilead Sciences News
- 2 days ago - Kymera outlines mid-2027 topline readout for KT-621 Phase IIb study as pipeline advances and Gilead partnership grows - Seeking Alpha
- 2 days ago - Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
- 2 days ago - See Which Of The Latest 13F Filers Holds GILD - Nasdaq
- 2 days ago - HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline - Nasdaq
- 2 days ago - Fernandez: The market is on a high wire right now - CNBC
- 3 days ago - Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025 - Business Wire
- 3 days ago - Kalaris appoints Matthew Gall as CFO - Seeking Alpha
- 6 days ago - Needham Reiterates Gilead Sciences (GILD) Buy Recommendation - Nasdaq